Eureka Lithium Corp. Files Amended LIFE Offering Document

Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - Eureka Lithium Corp. (CSE: ERKA) (OTCQB: UREKF) (FSE: S58) ("Eureka Lithium" or "Eureka" or the "Company") announces that it has filed an amended and restated LIFE Offering Document (the "Amended Offering Document") effective March 11, 2026, which amends the offering document filed by the Company on March 11, 2026. The amendment is required as the exercise price applicable to certain warrants being offered by the Company under the Life Offering (defined below) and a concurrent private placement are being priced at $0.50 as opposed to $0.45 as originally contemplated. Further details are below.

The Amended Offering Document relates to a non-brokered private placement financing under the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions (the "LIFE Exemption") of up to 4,761,904 units of the Company (the "Units") at a price of $0.42 per Unit for aggregate gross proceeds of up to $2,000,000 (the "LIFE Offering"). Each Unit will be comprised of one common share (the "Common Shares") and one Common Share purchase warrant (the "Warrants"). Each Warrant will entitle the holder to purchase one (1) Common Share (the "Warrant Shares") at an exercise price of $0.50 per Warrant Share for a period of 24 months from the closing date of the LIFE Offering. The Warrants will be governed by the terms and conditions set forth in the certificates representing the Warrants.

The Company also intends to complete two concurrent non-brokered private placements (the "Concurrent Offerings"). First, an offering of up to 4,761,904 units (the "Concurrent Private Placement Units") at a price of $0.42 per Concurrent Private Placement Unit for aggregate gross proceeds of up to $2,000,000. Each Concurrent Private Placement Unit will be comprised of one Common Share and one Common Share purchase warrant (the "Concurrent Private Placement Warrants"), and with each Concurrent Private Placement Warrant being exercisable for a period of 24 months, to acquire one Common Share (the "Concurrent Private Placement Warrant Shares") at an exercise price of $0.50 per Concurrent Private Placement Warrant Share.